ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Safety of hCG for Men with Hypogonadal Symptoms and Testosterone >300 ng/dL
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 223331" data-attributes="member: 13851"><p><strong>Safety of Human Chorionic Gonadotropin Monotherapy for Men with Hypogonadal Symptoms and Testosterone >300 ng/dL (2022)</strong></p><p><em>QRainer, RPai, TMasterson</em></p><p></p><p></p><p><strong>Introduction</strong></p><p></p><p><em>Human chorionic gonadotropin (hCG) is homologous to luteinizing hormone (LH) and is known to stimulate endogenous testosterone (T) production and may be an option for testosterone replacement therapy (TRT). Current guidelines recommend TRT for men with two T levels <300 ng/dl and symptoms of low T. A challenging patient population are men with symptoms of low T who do not meet biochemical criteria for TRT as there are no current treatments recommendations. We hypothesize that hCG may be a safe and effective therapy for men with hypogonadal symptoms and T >300ng/dl.</em></p><p></p><p></p><p><strong>Objective</strong></p><p><strong></strong></p><p><strong><em>Our objective was to evaluate for symptom improvement and side effects of hCG monotherapy in men with hypogonadal symptoms and T >300 ng/dL.</em></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Methods</strong></p><p></p><p><em><strong>We retrospectively reviewed the charts of 31 men treated with hCG monotherapy for hypogonadal symptoms with a T average (latest two lab results) >300 ng/dL who had follow-up labs at least 1 month after initiation of hCG therapy. We evaluated changes in hormones [T, LH, follicle-stimulating hormone (FSH), and estradiol], hematocrit (HCT), glycated hemoglobin (A1c), and prostate-specific antigen (PSA). Results are presented as means standard deviation. Student t-test was used to compare pre-and post-treatment values, significance was set at p=0.05. We also evaluated the incidence of thromboembolic events, including stroke, deep vein thrombosis, and myocardial infarction.</strong></em></p><p></p><p></p><p><strong>Results</strong></p><p></p><p><em><strong>The average age of patients was 49.0±15.8 years with a BMI of 28.6±4.8 kg/m2. Average follow-up after starting hCG therapy was 292 days, range 77 to 857 days. <u>The average weekly hCG dosage was 1500 IU</u>. Serum T increased from 431.27±117.22 ng/dL to 461.05 ±185.19 ng/dL (p=0.61, n=31). No change was seen in FSH (6.79±10.85 to 7.12±12.07 mIU/mL, n=8), PSA (1.55±1.44 to 1.90±1.81 ng/mL, n=10), HCT (43.43±2.27 to 44.48±2.86 %, n=12), estradiol (27.44±6.92 to 30.63±10.25 pg/mL, n=8), or A1c (6.15±0.95 to 6.33±0.93 %,n=4). A statistically significant decrease was seen in LH (4.93±1.98 to 3.66±1.85 mIU/mL,n=11). When evaluated for improvement of erectile dysfunction (ED, n=22), low libido (n=25), and low energy (n=19), 86%, 80%, and 79% of patients reported improvement of each symptom, respectively. All patients with ED were noted to be on another medication or therapy specifically for ED. No thromboembolic events were observed.</strong></em></p><p></p><p></p><p><strong>Conclusions</strong></p><p></p><p><strong><em>Weekly hCG dosing appears to safely improve hypogonadal symptoms even with baseline T levels >300 ng/dL. No changes were noted in HCT, PSA, A1c and no thromboembolic events were recorded.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 223331, member: 13851"] [B]Safety of Human Chorionic Gonadotropin Monotherapy for Men with Hypogonadal Symptoms and Testosterone >300 ng/dL (2022)[/B] [I]QRainer, RPai, TMasterson[/I] [B]Introduction[/B] [I]Human chorionic gonadotropin (hCG) is homologous to luteinizing hormone (LH) and is known to stimulate endogenous testosterone (T) production and may be an option for testosterone replacement therapy (TRT). Current guidelines recommend TRT for men with two T levels <300 ng/dl and symptoms of low T. A challenging patient population are men with symptoms of low T who do not meet biochemical criteria for TRT as there are no current treatments recommendations. We hypothesize that hCG may be a safe and effective therapy for men with hypogonadal symptoms and T >300ng/dl.[/I] [B]Objective [I]Our objective was to evaluate for symptom improvement and side effects of hCG monotherapy in men with hypogonadal symptoms and T >300 ng/dL.[/I] Methods[/B] [I][B]We retrospectively reviewed the charts of 31 men treated with hCG monotherapy for hypogonadal symptoms with a T average (latest two lab results) >300 ng/dL who had follow-up labs at least 1 month after initiation of hCG therapy. We evaluated changes in hormones [T, LH, follicle-stimulating hormone (FSH), and estradiol], hematocrit (HCT), glycated hemoglobin (A1c), and prostate-specific antigen (PSA). Results are presented as means standard deviation. Student t-test was used to compare pre-and post-treatment values, significance was set at p=0.05. We also evaluated the incidence of thromboembolic events, including stroke, deep vein thrombosis, and myocardial infarction.[/B][/I] [B]Results[/B] [I][B]The average age of patients was 49.0±15.8 years with a BMI of 28.6±4.8 kg/m2. Average follow-up after starting hCG therapy was 292 days, range 77 to 857 days. [U]The average weekly hCG dosage was 1500 IU[/U]. Serum T increased from 431.27±117.22 ng/dL to 461.05 ±185.19 ng/dL (p=0.61, n=31). No change was seen in FSH (6.79±10.85 to 7.12±12.07 mIU/mL, n=8), PSA (1.55±1.44 to 1.90±1.81 ng/mL, n=10), HCT (43.43±2.27 to 44.48±2.86 %, n=12), estradiol (27.44±6.92 to 30.63±10.25 pg/mL, n=8), or A1c (6.15±0.95 to 6.33±0.93 %,n=4). A statistically significant decrease was seen in LH (4.93±1.98 to 3.66±1.85 mIU/mL,n=11). When evaluated for improvement of erectile dysfunction (ED, n=22), low libido (n=25), and low energy (n=19), 86%, 80%, and 79% of patients reported improvement of each symptom, respectively. All patients with ED were noted to be on another medication or therapy specifically for ED. No thromboembolic events were observed.[/B][/I] [B]Conclusions[/B] [I][B][/B][/I] [B][I]Weekly hCG dosing appears to safely improve hypogonadal symptoms even with baseline T levels >300 ng/dL. No changes were noted in HCT, PSA, A1c and no thromboembolic events were recorded.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Safety of hCG for Men with Hypogonadal Symptoms and Testosterone >300 ng/dL
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top